DURHAM, N.C., July 9, 2026
Atsena Therapeutics announced the selection of ATSN-401 as its lead clinical candidate for the treatment of Stargardt disease (STGD), advancing the investigational gene therapy into IND-enabling studies. Designed as a potential best-in-class treatment, ATSN-401 aims to address the underlying genetic cause of Stargardt disease, the most common inherited macular dystrophy, by delivering a full-length functional ABCA4 gene directly to retinal photoreceptor cells. The program combines Atsena’s proprietary dual-vector DNA recombination platform with its innovative AAV.SPR laterally spreading capsid, enabling efficient delivery of the large ABCA4 gene throughout the central retina while avoiding surgical detachment of the fragile macula. With no approved therapies currently available to treat the genetic cause of Stargardt disease, ATSN-401 represents an important advancement in the company’s expanding inherited retinal disease pipeline.
Proprietary Dual-Vector Platform Enables Full-Length ABCA4 Gene Delivery
ATSN-401 is specifically designed to overcome one of the biggest challenges in ocular gene therapy—the large size of the ABCA4 gene, which exceeds the carrying capacity of conventional single adeno-associated virus (AAV) vectors. Atsena’s proprietary dual-vector DNA recombination technology divides the ABCA4 gene across two AAV vectors that recombine inside retinal cells after administration, producing a full-length functional ABCA4 protein. The therapy also incorporates the company’s proprietary AAV.SPR capsid, engineered to spread laterally from a peripheral retinal injection site into the central retina. This unique capability may allow retinal surgeons to avoid direct injection into the already damaged macula, potentially offering a significant safety advantage compared with conventional retinal gene therapy approaches while maintaining efficient delivery to diseased photoreceptors.
Preclinical Studies Demonstrate Strong Expression, Efficacy, and Safety
According to Atsena Therapeutics, the selected ATSN-401 clinical candidate demonstrated strong performance across key preclinical evaluation criteria, including gene expression, therapeutic efficacy, and safety in both mouse and non-human primate models. Researchers observed robust and correctly localized ABCA4 protein expression, significant reduction of harmful bisretinoid compounds, and favorable tolerability at therapeutic dose levels. The AAV.SPR laterally spreading capsid successfully distributed therapeutic genetic material throughout the central retina following peripheral administration, confirming its ability to reach critical retinal regions affected by Stargardt disease. These findings support the company’s belief that ATSN-401 has the potential to differentiate itself from other investigational therapies by combining effective gene replacement with a potentially less invasive delivery strategy.
Advertisement
ATSN-401 Expands Atsena’s Growing Inherited Retinal Disease Pipeline
Stargardt disease affects approximately 60,000 patients across the United States, Canada, and the European Union and typically begins during childhood or adolescence, causing progressive central vision loss due to mutations in the ABCA4 gene. The absence of approved disease-modifying treatments continues to represent a significant unmet medical need. With ATSN-401 now entering IND-enabling studies, Atsena Therapeutics continues to strengthen its portfolio of gene therapies targeting inherited retinal diseases. The company’s pipeline also includes ATSN-201, currently in a pivotal Phase 3 clinical trial for X-linked retinoschisis (XLRS), ATSN-101 for Leber congenital amaurosis type 1 (LCA1), and additional investigational programs for Usher Syndrome Type 1B and other rare inherited retinal disorders. By leveraging proprietary gene delivery technologies designed to improve both efficacy and safety, Atsena aims to develop next-generation therapies capable of preventing or reversing blindness caused by inherited genetic eye diseases.
Source: Atsena Therapeutics press release
